# Anti-Cancer Drug Screening with Microfluidic Technology
## 4 Combinatorial Drug Screening on a Microscale Sample
### 3D Cell Cultures
\begin{table}
\begin{tabular}{c c c c} \hline \hline \multicolumn{4}{c}{**Monodrug Screening on a Microscale Sample**} \\ \hline \hline \multicolumn{4}{c}{**Sample Type**} & **Tested Drugs** & **Number of Dosages Tested** & **Ref.** \\ \hline
3D spheroids from LCC6/Her-2 breast tumor cells & Doxorubicin & 4 & [42] \\ \hline
3D hydrogel from human ductal breast epithelial tumor cell line (T47D), human non-small cell lung cancer cell line (PC9), and adult human dermal blood microvascular endothelial cells (HMVEC) & Tareeva, staurosporine, and TNF-\(\alpha\) with cycloheximide & 1 & [43] \\ \hline
3D hydrogel from human glioma U251 cell line and three primary GBM cells & 24 different anti-cancer drugs & 6 & [34] \\ \hline Homogeneous 3D spheroids from either mesothelioma cell line & & Mono-culture: 10 Co-culture (with primary) \\ (H2052) or epithelial adenocarcinoma primary cells & & & perytes): 6 \\ \hline Spheroids from carcinoma (HepG2) cell line & Doxorubicin and paclitaxel & 3 & [45] \\ \hline Similarly sized 3D tumor spheroids from human glioma U251 cells & Vincristine and bleomycin & 6 & [46] \\ \hline
3D hydrogel from human epithelial cell line derived from cervical carcinoma (Hela) & Doxorubicin & 5 & [47] \\ \hline Human breast adenocarcinoma cell line (MCF-7), hepatocellular carcinoma cell line (HepG2), and normal human fetal liver cells (L-02) & Paclitaxel, doxorubicin, quercetin, and rutin & 6 & [30] \\ \hline
3D gel matrix from B16-F10 mouse melanoma, 4T1 mouse breast cancer and DU 145 human prostate cancer cell lines & Carboplatin and paclitaxel & 5 & [48] \\ \hline Cell lines and patient-derived breast cancer organoids & Bevacizumab, TGF8, and paclitaxel & 4 & [49] \\ \hline
3D spheroids from primary human prostate cancer cells & Enzalutamide, docetaxel, or cisplatin & 8 & [35] \\ \hline \multicolumn{4}{c}{Monodrug screening on a macroscale sample} \\ \hline \multicolumn{4}{c}{**Sample Type**} & **Tested Drugs** & **Number of Dosages Tested** & **Ref.** \\ \hline Both the organotypic and GBM xenograft mouse brain slice cultures & Staurosporine & 7 & [52] \\ \hline GBM xenografts and patient-derived colorectal cancer tumor slices. & 17-AAG, bortezomib, cisplatin, DMSO, moettinostal, MLN 2238, and parthenolide & 1 & [53] \\ \hline Micro-dissected tumor (MDT) tissues (4 mouse xenografts derived from human cancer cell lines, 3 from ovarian and prostate cancer patients, and 1 from a patient with benign prostatic hyperplasia) & Carboplatin & 1 & [54] \\ \hline Cell lines and patient-derived breast cancer organoids & Bevacizumab, TGF8, and paclitaxel & 4 & [49] \\ \hline Uniformly sized cuboids of normal mouse liver and human glioma xenograft tumors (U87) & Cisplatin & 3 & [55] \\ \hline \multicolumn{4}{c}{Combinatorial drug screening on a microscale sample} \\ \hline \multicolumn{4}{c}{**Sample Type**} & **Tested Drugs** & **Number of Combinations Tested** & **Ref.** \\ \hline Human & \multirow{2}{*}{5-fluorouracil and cyclophosphamide} & \multirow{2}{*}{65} & [58] \\ \cline{1-1} uterine cervix cancer (HeLa) cells & & & \\ \hline PC3 prostate cancer cells (PC3) & Doxorubicin or mitoavantrone with TRAIL & \multirow{2}{*}{64} & [60] \\ \cline{1-1} \cline{4-4}  & (TNF-alpha related apoptosis inducing ligand) either sequentially or simultaneously & & [61] \\ \hline Human prostate cancer PC3 cells & Curcumin and TRAIL & 64 & [61] \\ \hline \multicolumn{4}{c}{Two genetically different pancreatic cancer cell lines, xenograft mouse models, and human solid tumor-derived cells} & \multirow{2}{*}{56} & [71] \\ \cline{1-1} \cline{4-4}  & & & \\ \end{tabular}
\end{table} 
Table 1: Cont.